Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFN005
- Development stage
- Unknown
- Lead developer
- Hefei Afana Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
AFN005 is an mRNA-based vaccine candidate developed by Hefei Afana Biotechnology for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver messenger RNA encoding the RSV fusion (F) protein, which is a key target for neutralizing antibodies. By instructing host cells to produce the F protein, AFN005 stimulates both humoral and cellular immune responses to protect against RSV-related lower respiratory tract disease. It is primarily being developed for use in high-risk populations, including infants and older adults, and represents a significant advancement in the application of mRNA technology beyond COVID-19.
- Other names
- respiratory syncytial virus mRNA vaccineRSV mRNA vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on AFN005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFN005.